MELBOURNE-BASED Specialised Therapeutics has unveiled an expansion plan which may see the company publicly list a subsidiary to co-fund future developments.
The initiative was confirmed by ceo Carlo Montagner at the official opening of the company's new Australian headquarters, a decade after he co-founded the business with Bozena Zembrzuski with a single chemotherapy product.
Since then Specialised Therapeutics has grown to what he claimed is the largest privately owned specialty pharma company in the region, with almost 50 staff and annual revenue around $30m.
Montagner attributed the company's success to a strategy of in-licensing mid- to late-stage products for full commercialisation, with the portfolio now spanning oncology, haemotology, neurology, ophthalmology & supportive care.
"Our vision for the first 10 years was to build a profitable pharmaceutical company partnering with leading global biotech and pharmaceutical companies," he said.
"While we continue to invest aggressively to further expand our global partnerships and product pipeline into new therapeutic areas, it is now time to build on these solid foundations and execute the next stage of our company's development," Montagner added.
The plan for the next 10 years includes in-licensing of earlier-stage drugs, steering them through full clinical development and then globally commercialising them.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Aug 18
